Actelion Pharmaceuticals Ltd.

The sponsor maintains a strong focus on pulmonary arterial hypertension (PAH), investigating therapeutic approaches for this progressive cardiovascular condition. Research encompasses both treatment-naïve patients and those previously exposed to therapy, examining novel pharmaceutical interventions designed to address the underlying pathophysiology of elevated pulmonary artery pressure. The clinical programme evaluates efficacy in improving exercise capacity, hemodynamic parameters, and overall clinical outcomes in adult populations affected by this rare but serious pulmonary vascular disorder.

• Pulmonary Arterial Hypertension Treatment
• Exercise Capacity Enhancement
• Hemodynamic Parameter Optimization

The therapeutic strategy addresses the complex vascular remodelling processes that characterize pulmonary hypertension, with particular attention to improving patient functional status and quality of life through targeted pharmacological modulation.